{
  "label": "clinical_signal_03_ep_008",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:5b65e3c900a9a14c74528fadd1a5aafef352e039916da4cb5c339eda12fbbecc",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:15.259246",
  "content": "## 2024-04-22 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 180\n- Active: 177\n- Screen Failures Cumulative: 13\n- Withdrawals Cumulative: 3\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 13\n- Site 02 Active: 13\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 16\n- Site 03 Active: 16\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 3\n- Site 06 Enrolled: 10\n- Site 06 Active: 10\n- Site 06 Statin Concomitant: 2\n- Site 07 Enrolled: 19\n- Site 07 Active: 19\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 13\n- Site 08 Active: 13\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 16\n- Site 11 Active: 16\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 13\n- Site 12 Active: 13\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 52\n- ALT (U/L) Mean: 25.0\n- ALT (U/L) Median: 22.3\n- AST (U/L) Mean: 20.6\n- AST (U/L) Median: 19.0\n- Bilirubin (mg/dL) Mean: 0.73\n- Bilirubin (mg/dL) Median: 0.7\n- ALP (U/L) Mean: 73.1\n- ALP (U/L) Median: 76.4\n- Creatinine (mg/dL) Mean: 0.81\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 15.6\n- BUN (mg/dL) Median: 12.5\n- WBC (K) Mean: 6.0\n- WBC (K) Median: 6.3\n- Platelets (K) Mean: 242\n- Platelets (K) Median: 244\n\n#### Non-Statin Subgroup\n- N: 130\n- ALT (U/L) Mean: 28.6\n- ALT (U/L) Median: 26.8\n- AST (U/L) Mean: 22.5\n- AST (U/L) Median: 20.5\n- Bilirubin (mg/dL) Mean: 0.57\n- Bilirubin (mg/dL) Median: 0.54\n- ALP (U/L) Mean: 50.6\n- ALP (U/L) Median: 66.5\n- Creatinine (mg/dL) Mean: 1.07\n- Creatinine (mg/dL) Median: 0.83\n- BUN (mg/dL) Mean: 17.3\n- BUN (mg/dL) Median: 16.2\n- WBC (K) Mean: 6.8\n- WBC (K) Median: 5.6\n- Platelets (K) Mean: 238\n- Platelets (K) Median: 233\n\n### Adverse Events\n- AE ID: AE-0023, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0024, Description: diarrhea, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n\n### Concomitant Meds\n- Statin Count: 56\n- ACE Inhibitor Count: 29\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 33\n\n### Protocol Deviations\n- PD ID: PD-019, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_09\n- PD ID: PD-020, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_04\n\n### Investigator Notes\n- Study drug accountability reconciled, no discrepancies\n- All SAE narratives submitted within reporting window\n- No new safety signals identified this week by local PI\n\n### Events\n- Site 06 monitoring visit completed, 2 findings\n- Regulatory submission packet sent to Site 05\n- IP resupply shipped to Sites 11, 12\n\n### Notes\n- Week 8: Enrollment target met. All hepatic and renal panels within normal limits. 2 minor protocol deviations.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_008",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-04-22T10:00:00",
    "phase": "baseline",
    "signal_density": "none",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}